Browsing Tag
Sickle Cell Disease
11 posts
Vertex Pharmaceuticals (Nasdaq: VRTX) gains FDA approval to expand Casgevy to children as young as two
Vertex Pharmaceuticals wins FDA approval to expand Casgevy to children as young as two, reshaping sickle cell treatment economics.
Agios shakes up sickle cell therapy landscape with mixed but promising RISE UP phase 3 data for mitapivat
Find out how Agios’ mixed but promising RISE UP phase 3 data for mitapivat could reshape sickle cell treatment and influence regulatory decisions.
Base editing vs CRISPR: Why Beam Therapeutics’ sickle cell therapy may quietly become a blockbuster
Weeks after Beam’s BEAM-101 earned RMAT status, here’s why base editing may still reshape sickle cell therapy—and what investors should watch next.
Zynext Ventures expands biotech portfolio with Illexcor’s sickle cell drug investment
Zynext Ventures USA LLC (Zynext Ventures), the venture capital division of Zydus Lifesciences, has announced a strategic investment…
FDA approves Vertex and CRISPR Therapeutics’ CASGEVY for sickle cell disease
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics have announced a significant milestone in medical science with the U.S. Food…
bluebird bio unveils US commercial strategy for LYFGENIA gene therapy
bluebird bio, Inc., a pioneer in the biotechnology industry, has announced the U.S. commercial infrastructure for LYFGENIA (lovotibeglogene…
Novo Nordisk acquires SCD drug developer Forma Therapeutics
Novo Nordisk acquisition of Forma Therapeutics : Danish pharma company Novo Nordisk has closed the previously announced $1.1…
Pfizer to acquire Oxbryta developer Global Blood Therapeutics for $5.4bn
Pfizer has agreed to acquire Global Blood Therapeutics (GBT), a publicly-listed American biopharma company, in a deal worth…
Ardent phase 2b clinical trial of IMR-687 : Imara wraps up patient enrollment
Imara Inc. said that it has wrapped up enrollment of patients in the Ardent phase 2b clinical trial…
Global Blood Therapeutics bags Oxbryta FDA approval for sickle cell disease
Oxbryta FDA approval : Global Blood Therapeutics (GBT), a California-based biopharma company, has bagged approval for Oxbryta (voxelotor)…